TERMINATED

A Study to Learn How Different Amounts of the Study Medicine Called PF-07314470 Are Tolerated and Act in the Body in Healthy Adults

Conditions

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of this clinical trial is to learn if the study medicine (called PF-07314470) is safe and how it gets in and out of the body in healthy people.

Official Title

A PHASE 1, RANDOMIZED, DOUBLE-BLIND, SPONSOR-OPEN, PLACEBO CONTROLLED, DOSE ESCALATING STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF SINGLE AND MULTIPLE SUBCUTANEOUS DOSES OF PF-07314470 IN HEALTHY PARTICIPANTS

Quick Facts

Study Start:2025-02-11

Study Completion:2025-08-18

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:TERMINATED

Study ID

NCT06821750

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 55 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:Yes

Standard Ages:ADULT

Inclusion Criteria	Exclusion Criteria
* Healthy males aged 18 to 45 years and healthy females aged 18 to 55 years * Body Mass Index (BMI) of 16-32 kg/m2, and a total body weight greater than 50 kg (110 lb); for Japanese participants only, a total body weight greater than 45 kg * for Japanese participants only, enrolling as Japanese must have 4 biological grandparents who were born in Japan.	* Evidence or history of clinically significant medical or psychiatric conditions * Prior or current use of any prohibited medications * History of alcohol abuse or repeated binge drinking and/or any other illicit drug use or dependence within 6 months of screening * Pregnant or breastfeeding females, males with partners currently pregnant, or males or females pursuing artificial reproductive technologies * Use of tobacco/nicotine containing products

Inclusion Criteria

Exclusion Criteria

* Healthy males aged 18 to 45 years and healthy females aged 18 to 55 years
* Body Mass Index (BMI) of 16-32 kg/m2, and a total body weight greater than 50 kg (110 lb); for Japanese participants only, a total body weight greater than 45 kg
* for Japanese participants only, enrolling as Japanese must have 4 biological grandparents who were born in Japan.

* Evidence or history of clinically significant medical or psychiatric conditions
* Prior or current use of any prohibited medications
* History of alcohol abuse or repeated binge drinking and/or any other illicit drug use or dependence within 6 months of screening
* Pregnant or breastfeeding females, males with partners currently pregnant, or males or females pursuing artificial reproductive technologies
* Use of tobacco/nicotine containing products

Contacts and Locations

Principal Investigator

Pfizer CT.gov Call Center

STUDY_DIRECTOR

Pfizer

Study Locations (Sites)

Pfizer Clinical Research Unit - New Haven

New Haven, Connecticut, 06511

United States

Collaborators and Investigators

Sponsor: Pfizer

Pfizer CT.gov Call Center, STUDY_DIRECTOR, Pfizer

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-02-11

Study Completion Date2025-08-18

Study Record Updates

Study Start Date2025-02-11

Study Completion Date2025-08-18

Terms related to this study

Additional Relevant MeSH Terms

Healthy